Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Tempus AI, Inc. has received a consensus recommendation of "Moderate Buy" from analysts, with six hold ratings and seven buy ratings across thirteen brokerages covering the stock.
• The average 12-month price target among analysts is $69.50, with price target increases from firms like Guggenheim and Morgan Stanley in recent reports.
• Tempus AI reported earnings of ($0.22) EPS, exceeding analyst expectations, and its revenue increased by 89.5% compared to the same quarter last year.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) has received a consensus rating of "Moderate Buy" from the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $69.50.

TEM has been the subject of several recent research reports. Piper Sandler reiterated a "neutral" rating on shares of Tempus AI in a research note on Friday, August 8th. Guggenheim boosted their price target on Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Morgan Stanley upped their target price on Tempus AI from $65.00 to $68.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 12th. Bank of America upped their target price on Tempus AI from $68.00 to $70.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 25th. Finally, Needham & Company LLC restated a "buy" rating and set a $70.00 target price on shares of Tempus AI in a research note on Friday, August 8th.

Tempus AI Trading Up 1.9%

Shares of TEM stock opened at $79.62 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58. The stock has a market cap of $13.83 billion, a P/E ratio of -66.91 and a beta of 5.08. The stock has a 50 day simple moving average of $65.39 and a 200 day simple moving average of $59.04. Tempus AI has a 1 year low of $31.36 and a 1 year high of $91.45.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The business had revenue of $314.64 million during the quarter, compared to analysts' expectations of $296.84 million. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The firm's revenue for the quarter was up 89.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. On average, research analysts predict that Tempus AI will post -6.15 earnings per share for the current fiscal year.

Insider Activity

In other Tempus AI news, EVP Erik Phelps sold 3,664 shares of the company's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total transaction of $273,517.60. Following the completion of the sale, the executive vice president directly owned 94,115 shares in the company, valued at $7,025,684.75. This represents a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Ryan Fukushima sold 17,460 shares of the company's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $1,303,389.00. Following the sale, the chief operating officer owned 839,180 shares of the company's stock, valued at $62,644,787. The trade was a 2.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,108,951 shares of company stock valued at $77,660,938. Corporate insiders own 26.27% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TEM. Vanguard Group Inc. increased its holdings in shares of Tempus AI by 6,247.5% during the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock worth $289,204,000 after buying an additional 5,900,668 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of Tempus AI by 35.9% during the first quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock worth $361,867,000 after buying an additional 1,981,755 shares in the last quarter. Nikko Asset Management Americas Inc. increased its holdings in shares of Tempus AI by 31.5% during the first quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock worth $205,401,000 after buying an additional 1,021,460 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Tempus AI by 31.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock worth $205,284,000 after buying an additional 1,016,384 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of Tempus AI during the second quarter worth $54,020,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.